Gilead Sciences, Inc. (ETR:GIS)

Market Cap	148.24B +32.5%
Revenue (ttm)	24.79B +2.8%
Net Income	6.91B +6,336.5%
EPS	5.47 +6,514.1%
Shares Out	n/a
PE Ratio	21.45
Forward PE	17.45
Dividend	2.76 (2.32%)
Ex-Dividend Date	Dec 15, 2025

Volume	694
Average Volume	1,931
Open	118.72
Previous Close	118.94
Day's Range	118.72 - 120.50
52-Week Range	82.04 - 120.46
Beta	0.35
RSI	72.93
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GIS

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD